Rigel Pharmaceuticals, Inc. — Q2 2014 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2014. Rigel is a clinical-stage drug developer; it had no marketed products and reported no collaboration revenue in the period. Financial amounts below are in U.S. dollars, in millions unless stated otherwise.
Financial results and liquidity
| Metric | Q2 2014 | Six months 2014 | Comparable 2013 |
|---|---|---|---|
| Collaboration revenue | $0 | $0 | $1.4 in both periods |
| Research and development expense | $20.1 | $36.9 | $19.4 quarterly; $39.7 six months |
| General and administrative expense | $5.4 | $10.9 | $4.9 quarterly; $10.3 six months |
| Net loss | $25.4 | $47.7 | $22.8 quarterly; $48.3 six months |
| Basic and diluted loss per share | $0.29 | $0.54 | $0.26 quarterly; $0.55 six months |
| Operating cash used | Not stated for quarter | $36.4 | $46.4 six months |
- At June 30, cash and cash equivalents were $23.9 and available-for-sale securities were $152.1, totaling $176.0, down from $212.0 at year-end 2013. Current assets were $177.5; current liabilities were $10.1; total assets were $182.4.
- Stockholders’ equity was $165.7 and accumulated deficit was $897.0. The balance sheet reports no conventional borrowing or debt balance. Contractual facilities lease commitments totaled $55.2, including $14.6 due within one year.
- Six-month investing cash inflow was $38.7, primarily reflecting net maturities of investments; financing cash inflow was $0.7. Cash and cash equivalents increased $3.0 to $23.9 during the six months.
- Gross margin is not applicable to the reported business results: there was no revenue in 2014, and the filing presents operating expenses rather than cost of sales.
Changes versus prior period
- Quarterly net loss widened to $25.4 from $22.8, principally alongside higher R&D and G&A expense and the absence of the prior-year $1.4 collaboration payment.
- Six-month net loss improved modestly to $47.7 from $48.3. R&D expense declined $2.8, reflecting completed or reduced trials, partly offset by higher fostamatinib ITP spending; G&A rose $0.6.
- Six-month operating cash use fell to $36.4 from $46.4. The filing attributes cash use primarily to R&D and ordinary operating expenses; working-capital timing also affected cash flows.
Outlook, commentary and risks
- Management believed existing capital resources would fund current and projected requirements through Q2 2016, but cautioned that assumptions could prove wrong. It expected R&D spending to increase during the remainder of 2014.
- Rigel initiated a Phase 3 fostamatinib program for ITP in July 2014, after quarter-end, involving two studies and 150 patients; top-line results were expected by the end of 2015. A Phase 2 IgA nephropathy trial was planned for the second half of 2014.
- R348 Phase 2 dry-eye results were expected in August 2014; the company had also initiated a Phase 2 R348 study for dry eye associated with ocular graft-versus-host disease. R118 had entered Phase 1 testing for intermittent claudication.
- The company had no product sales or royalty revenue. Potential collaboration milestones exceeding $152.3 were contingent on partners achieving development, regulatory, or commercial events and were not assured.
- Key risks include clinical failure or delay, uncertain regulatory approval, dependence on external manufacturers and collaborators, and the need for additional capital. New equity could dilute shareholders; debt or licensing arrangements could impose restrictions or require rights concessions. Fostamatinib’s prior rheumatoid arthritis program was discontinued after partner AstraZeneca declined to pursue filings and returned rights.
- No legal proceedings were reported. Management said disclosure controls were effective as of quarter-end and reported no material internal-control changes during the quarter.
Important facts for investors to verify
- Progress, enrollment, safety and results for fostamatinib’s ITP Phase 3 program, and whether the planned IgA nephropathy study commenced.
- R348 dry-eye results and subsequent development plans, including the ocular graft-versus-host disease study; progress of R118 Phase 1 testing.
- Cash burn and investment balances against management’s Q2 2016 funding estimate, particularly as R&D spending was expected to rise.
- Availability and terms of future financing or collaboration funding; contingent milestones should not be treated as committed cash.
- Clinical manufacturing and supply readiness, and the substantial lease commitments disclosed in the filing.